

IFW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/694,921	
	Filing Date	October 27, 2003	
	First Named Inventor	Fujio Suzuki	
	Art Unit	1764	
	Examiner Name	Not yet assigned	
Total Number of Pages in This Submission	56	Attorney Docket Number	SHX 332


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Form PTO-1449, 12 references, return postcard.
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Anton E. Skaugset Kolisch Hartwell, P.C.
Signature	
Date	August 12, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Suzanne Werner
Signature	
Date	August 12, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fujio Suzuki, et al.

Date: August 12, 2004

Serial No. : 10/694,921

Our Ref.: SHX 332

Filed : October 27, 2003

Group Art Unit: 1764

For : USE OF GLYCYRRHIZIN AND ITS DERIVATIVES AS
RANTES INDUCERS

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56, 1.97, and 1.98

Applicants are submitting this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98 to disclose to the U.S. Patent and Trademark Office the patents, publications, applications, and/or other references listed on the enclosed, completed PTO-1449 form(s). The filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or as an admission that the listed references are prior art for this application. Applicants respectfully request that the listed references be expressly considered during prosecution of the application, and that the references be made of record therein and appear among the "references cited" on any patents issuing therefrom.

CONTENT OF DISCLOSURE

This Information Disclosure Statement includes (1) two pages of PTO-1449 forms, and (2) a legible copy of each foreign and non-patent reference, if any, listed on the form(s). However, because this application was filed on or after July 1, 2003, no copies of U.S. patents or published U.S. patent applications are included.

FOREIGN-LANGUAGE REFERENCES

A concise explanation of the relevance of each listed reference not in the English language follows:

European Patent No. 0687465: The use of Glycyrrhizin Acid and its metabolite (Glycyrrhizin Acid) as a drug in the preparation of a medicament in the treatment of viral and allergic diseases.

TIMING OF DISCLOSURE / FEE INFORMATION

This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, either (1) before the mailing of a first Office action on the merits, or (2) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. § 1.114. Moreover, in accordance with 37 C.F.R. § 1.97(e)(1), the undersigned states that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the

filing of this Information Disclosure Statement. Therefore, in accordance with 37 C.F.R. §§ 1.97(b)(3), (b)(4), or (c)(1), no fee is required.

Please contact the undersigned with any questions or comments regarding this Information Disclosure Statement.

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on August 12, 2004.



Suzanne Werner

Respectfully submitted,

KOLISCH HARTWELL, P.C.



Anton E. Skaugset

Registration No. 38,617

Customer No. 23581


520 S.W. Yamhill Street, Suite 200

Portland, Oregon 97204

Telephone: (503) 224-6655


Facsimile: (503) 295-6679

Attorney/Agent for Applicant/Assignee



SHEET 1 OF 2

FORM PTO-1449		DOCKET NUMBER SHX 332		APPLICATION NUMBER 10/694,921		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT(S) Fujio Suzuki, et al.				
		FILING DATE October 27, 2003		GROUP ART UNIT 1764		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPROP.
	2002/0091158	7/11/2002	Flore			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	06135836	5/17/1994	Japan			
	0255420	02/03/1988	EPO			X
	0687465	12/20/1995	EPO			X
OTHER DOCUMENTS						
	Suzuki F., et al., <i>The Induction Of Beta-Chemokines By Glycyrrhizin (GR), An Active Component Of Licorice Roots, in Cultures Of Peripheral Blood Mononuclear Cells</i> , Journal Of Allergy And Clinical Immunology, Vol. 105, No. 1, Part 2, January 2000, Page S113.					
	Utsunomiya Tokuichiro, et al., <i>Glycyrrhizin Improves the Resistance of MAIDS Mice to Opportunistic Infection of Candida Albicans through the Modulation of MAIDS-Associated Type 2 T Cell Responses</i> , Clinical Immunology, Academic Press, U.S., Vol. 95, No. 2, May 2000, Pages 145-155.					
	Utsunomiya T., et al., <i>Effects of Glycyrrhizin, an Active Component of Licorice Roots, on Candida Albicans Infection in Thermally Injured Mice</i> , Clinical and Experimental Immunology, Oxford, GB, Vol. 116, No. 2, May 1999, Pages 291-298.					
	Kobayashi M., et al., <i>Inhibition of Burn-Associated Suppressor Cell Generation by Glycyrrhizin through the Induction of Contrasuppressor T Cells</i> , Immunology and Cell Biology, Vol. 71, No. 3, 1993, Pages 181-189.					
	Badam Lalita, <i>Glycyrrhizin: an Alternate Drug for Pneumocystis Carinii Pneumonia in AIDS Patients</i> , The Journal of the Association of Physicians of India, India, Vol. 50, Feb. 2002 (2002-02), Pages 287-288.					
	Utsunomiya T., et al., <i>Glycyrrhizin (20 Beta-Carboxy-11-Oxo-30-Norolean-12-En-3-Beta-Yl-2-O-Beta-D-Glycopyranuronosyl-Alpha-D-Glucopyranosiduronic Acid) Improves the Resistance of Terminally Injured Mice to Opportunistic Infection of Herpes Simplex Virus Type 1</i> , Immunology Letters, Amsterdam, NL, Vol. 44, 1995, Pages 59-66.					
EXAMINER			DATE CONSIDERED			

SHEET 2 OF 2

FORM PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION		DOCKET NUMBER SHX 332		APPLICATION NUMBER 10/694,921		
		APPLICANT(S) Fujio Suzuki, et al.				
		FILING DATE October 27, 2003		GROUP ART UNIT 1764		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPROP.
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
OTHER DOCUMENTS						
	Sekizawa T., et al., <i>Glycyrrhizin Increases Survival of Mice with Herpes Simplex Encephalitis</i> , ACTA Virologica, Academia Prague, Prague, CZ, Vol. 45, No. 1, Feb. 2001 (2001-02), Pages 51-54.					
	Badam Lalita, <i>In Vitro Antiviral Activity of Indigenous Glycyrrhizin, Licorice and Glycyrrhizic Acid (Sigma) on Japanese Encephalitis Virus</i> , Journal of Communicable Diseases, Vol. 29, No. 2, 1997, Pages 91-99.					
	Coffey, Michael J., et al., <i>Rantes, Inhibits HIV-1 Replication in Human Peripheral Blood Monocytes and Alveolar Macrophages</i> , American Journal of Physiology, Vol. 272, No. 5, Part 1, 1997, Pages L1025-L1029.					
EXAMINER			DATE CONSIDERED			